REG - Oxford Cannabinoid - Director/PDMR Share Purchases

Oxford Cannabinoid Technologies HoldingsAnnouncement

17/07/2023 13:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230717:nRSQ2585Ga&default-theme=true

RNS Number : 2585G  Oxford Cannabinoid Tech.Holdings  17 July 2023

17 July 2023

Oxford Cannabinoid Technologies Holdings plc

PDMR and Director Dealings

Oxford Cannabinoid Technologies Holdings plc ("the Company"), announces that
it has been informed today that Clarissa Sowemimo-Coker, Chief Executive
Officer and Robin Bennett, General Counsel and Company Secretary have today
purchased ordinary shares of £0.01 in the Company ("Ordinary Shares").

 Director/PDMR            Total number of Ordinary Shares purchased  Price per Ordinary Share  Number of Ordinary Shares held following the purchase
 Clarissa Sowemimo-Coker  310,406                                    £0.009064                 1,500,000

 Robin Bennett            331,012                                    £0.009                    331,012

 

The PDMR forms are set out
below.

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018).

The Directors of the Company accept responsibility for the content of this
announcement.

 

Enquiries:

 Oxford Cannabinoid Technologies Holdings plc  +44 (0)20 3034 2820

 Clarissa Sowemimo-Coker (CEO)                 clarissa@oxcantech.com

 Cairn Financial Advisers LLP

 Emily Staples                                 +44 (0)20 7213 0897

 Jo Turner                                     +44 (0) 20 7213 0885

 Axis Capital Markets Limited

 Richard Hutchison                             +44 (0)20 3026 0320

 Walbrook PR Limited

 Paul Vann/Nick Rome/Joe Walker                +44 (0)20 7933 8780

                                               +44 (0)7768 807631

                                               oxcantech@walbrookpr.com (mailto:oxcantech@walbrookpr.com)

 

About Oxford Cannabinoid Technologies Holdings Plc:

Oxford Cannabinoid Technologies Holdings plc ("OCTP") is the holding company
of Oxford Cannabinoid Technologies Ltd (together the "Group"), a
pharmaceutical Group developing prescription cannabinoid medicines targeting
the U$ multi-billion global pain market.

 

OCTP currently has a portfolio of four drug development programmes. Its lead
compound, OCT461201, will initially target neuropathic and visceral pain
(including irritable bowel syndrome ("IBS") and chemotherapy induced
peripheral neuropathy ("CIPN")), with the Phase I clinical trial, aimed at
demonstrating safety and tolerability. Trial results are expected in Q3
2023.
(https://www.londonstockexchange.com/news-article/OCTP/updates-on-lead-programme-1-and-programme-2/15391762)
The global market for CIPN alone is currently valued at US$1.61bn and is
forecast to reach US$2.37bn by the year 2027.

 

OCTP's drug development pipeline comprises both natural and synthetic
compounds, and includes compounds targeting trigeminal neuralgia, a severe
type of face pain, and cannabinoid derivatives targeting pain and potentially
other therapeutic areas. Having established an exclusive license agreement
with Canopy Growth Corporation for their entire pharmaceutical cannabinoid
derivative library, OCTP now has a portfolio of almost five hundred
derivatives and intellectual property rights including fourteen patent
families and associated research data.

 

OCTP has a clearly defined path to commercialisation, revenues and growth. The
Group is developing drug candidates through clinical trials to gain regulatory
approval (FDA/MHRA/EMA) that will enable medical professionals to prescribe
them with confidence. OCTP's portfolio aims to balance risk, value and time to
market, whilst ensuring market exclusivity around all its key activities.

 

 Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
 596/2014
 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a.  Name                                                         Clarissa Sowemimo-Coker
 2   Reason for notification

 a.  Position/Status                                              Chief Executive Officer
 b.  Initial notification/                                        Initial notification

     Amendment
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a.  Name                                                         Oxford Cannabinoid Technologies Holdings plc
 b.  LEI

                                                                  2138005SRWT4998BCE35

 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument

Identification Code                                         Ordinary shares of £0.01 each

                                                                  GB00BMVMRB86
 b.  Nature of the transaction                                    Acquisition of ordinary shares of £0.01 each
 c.  Price(s) and volume(s)
                                                                              Price(s)    Volume(s)
     £0.009064                                                                310,406

 d.  Aggregated information                                       N/A - single transaction

     - Aggregated Volume

     - Price
 e.  Date of the transaction                                      17 July 2023
 f.  Place of the transaction                                     London, UK

 

 Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
 596/2014
 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a.  Name                                                         Robin Bennett
 2   Reason for notification

 a.  Position/Status                                              General Counsel and Company Secretary
 b.  Initial notification/                                        Initial notification

     Amendment
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a.  Name                                                         Oxford Cannabinoid Technologies Holdings plc
 b.  LEI

                                                                  2138005SRWT4998BCE35

 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument

Identification Code                                         Ordinary shares of £0.01 each

                                                                  GB00BMVMRB86
 b.  Nature of the transaction                                    Acquisition of ordinary shares of £0.01 each
 c.  Price(s) and volume(s)
                                                                              Price(s)    Volume(s)
     £0.009                                                                   331,012

 d.  Aggregated information                                       N/A - single transaction

     - Aggregated Volume

     - Price
 e.  Date of the transaction                                      17 July 2023

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHMZGMNZNDGFZM